Skip to main content

Table 2 Clinico-pathological characteristics

From: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis

Local/regional recurrence cohort (n = 41)n (%)
Age, median (range)51 (27–84)
Subtypes 
 ER+/HER2−23 (56%)
 ER+/HER2+6 (15%)
 ER+/HER2 unknown12 (29%)
T stage at diagnosis
 T125 (61%)
 T213 (32%)
 T31 (2%)
 T41 (2%)
LN+ at diagnosis17 (41%)
Neoadjuvant endocrine treatment2 (5%)
Endocrine treatments pre-biopsy
 Tamoxifen only23 (56%)
 Aromatase inhibitors (AI)5 (12%)
 Tamoxifen + AI13 (32%)
Adjuvant/NAT chemotherapy
 Adjuvant16 (39%)
 Neoadjuvant10 (24%)
Local/regional recurrence type
 Local recurrence22 (54%)
 Regional recurrence19 (46%)
 Unknown1 (2%)
Distant recurrence12 (29%)
Median follow-up time from diagnosis, years (range)12 (4–24)
Median follow-up time from first local recurrence, years (range)5 (0–20)
Median follow-up time from tested local recurrence, years (range)4 (0–17)